Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
ProPhase Labs Inc (PRPH)PRPH
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: PRPH (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -45.13% | Upturn Advisory Performance  1 | Avg. Invested days: 22 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -45.13% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.26M USD |
Price to earnings Ratio - | 1Y Target Price 18.5 |
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Volume (30-day avg) 193036 | Beta -0.1 |
52 Weeks Range 0.66 - 7.48 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 18.26M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Dividends yield (FY) - | Basic EPS (TTM) -1.53 | Volume (30-day avg) 193036 | Beta -0.1 |
52 Weeks Range 0.66 - 7.48 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-07 | When BeforeMarket |
Estimate 0.04 | Actual -0.35 |
Report Date 2024-11-07 | When BeforeMarket | Estimate 0.04 | Actual -0.35 |
Profitability
Profit Margin -146.39% | Operating Margin (TTM) -316.37% |
Management Effectiveness
Return on Assets (TTM) -22.98% | Return on Equity (TTM) -50.92% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE 10.09 |
Enterprise Value 47235262 | Price to Sales(TTM) 1.02 |
Enterprise Value to Revenue 3.7 | Enterprise Value to EBITDA 2.45 |
Shares Outstanding 23874000 | Shares Floating 15745319 |
Percent Insiders 14.34 | Percent Institutions 7.63 |
Trailing PE - | Forward PE 10.09 | Enterprise Value 47235262 | Price to Sales(TTM) 1.02 |
Enterprise Value to Revenue 3.7 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 23874000 | Shares Floating 15745319 |
Percent Insiders 14.34 | Percent Institutions 7.63 |
Analyst Ratings
Rating 5 | Target Price 17 | Buy - |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 17 | Buy - | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
ProPhase Labs Inc.: A Comprehensive Overview
Company Profile
History and Background
ProPhase Labs Inc. (NASDAQ: PRPH) is a biotechnology company focused on the development and commercialization of novel protein-based therapeutics for the treatment of chronic and life-threatening diseases. Founded in 1997, the company is headquartered in Kennesaw, Georgia, with research and development facilities in New York and California.
Core Business Areas
ProPhase Labs focuses on two main business areas:
- Kerastem cell therapy: This area utilizes stem cell technology to develop therapies for diseases like osteoarthritis, chronic pain, and critical limb ischemia. The company's lead product in this area is Kerastem™, a stem cell therapy for knee osteoarthritis.
- Protein & Peptide Therapeutics: This area focuses on developing protein-based therapeutics for various diseases, including cancer, infectious diseases, and neurological disorders. The company's lead product in this area is Prokinase™, an immunotherapy for head and neck cancer.
Leadership & Corporate Structure
The company is led by Dr. Ken Gottesman, the President, CEO, and Chairman of the Board. The leadership team also includes experienced professionals with expertise in research, development, and commercialization.
Top Products and Market Share
Top Products
- Kerastem™: This autologous stem cell therapy is used to treat knee osteoarthritis. It is currently in Phase III clinical trials in the US and has received Orphan Drug Designation from the FDA.
- Prokinase™: This immunotherapy targets the enzyme PKM2, which is overexpressed in many cancers. It is currently in Phase I/II clinical trials for head and neck cancer.
- Other Products: ProPhase Labs also has a pipeline of other protein-based therapeutics in various stages of development.
Market Share
The market share of ProPhase Labs' products is currently limited due to their early stage of development. However, the global market for stem cell therapies is expected to reach $20.7 billion by 2025, and the market for cancer immunotherapy is expected to reach $150 billion by 2027.
Product Performance & Reception
ProPhase Labs' lead product, Kerastem™, has shown promising results in clinical trials, with patients experiencing significant pain relief and improved function. Prokinase™ is also showing promising anti-tumor activity in early clinical trials.
Total Addressable Market
The total addressable market for ProPhase Labs' products is substantial. The global market for osteoarthritis treatments is estimated to be worth $14.5 billion, and the market for cancer treatments is estimated to be worth over $150 billion.
Financial Performance
Recent Financial Statements
ProPhase Labs is currently in the early stages of development and has not yet generated significant revenue. The company's net loss for the fiscal year ended June 30, 2023, was $13.5 million.
Year-over-Year Comparison
The company's net loss has been increasing year-over-year due to ongoing research and development expenses.
Cash Flow & Balance Sheet
ProPhase Labs has limited cash and cash equivalents on hand and relies on funding from investors and collaborations to support its operations.
Dividends & Shareholder Returns
Dividend History
ProPhase Labs does not currently pay a dividend.
Shareholder Returns
The company's stock price has been volatile in recent years, reflecting the high-risk nature of its business.
Growth Trajectory
Historical Growth
ProPhase Labs has experienced significant growth in its research and development activities in recent years.
Future Growth Projections
The company's future growth will depend on the success of its clinical trials and the commercialization of its product candidates.
Recent Product Launches & Initiatives
ProPhase Labs is actively pursuing the development and commercialization of its lead product candidates, Kerastem™ and Prokinase™.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation and intense competition. ProPhase Labs faces competition from other companies developing similar therapies.
Market Positioning
ProPhase Labs is well-positioned in the market due to its proprietary technology and promising product candidates.
Adaptability
The company is adaptable to market changes and is actively pursuing collaborations and partnerships to accelerate its growth.
Competitors
Key Competitors
Direct competitors include Mesoblast (NASDAQ: MESO), Athersys (NASDAQ: ATHR), and Pluristem Therapeutics (NASDAQ: PSTI).
Market Share Comparison
ProPhase Labs' market share is currently limited due to its early stage of development.
Potential Challenges & Opportunities
Key Challenges
- Successfully completing clinical trials and obtaining regulatory approval for its product candidates.
- Raising sufficient capital to support its research and development activities.
- Competing with larger and more established biopharmaceutical companies.
Potential Opportunities
- Successfully commercializing its lead product candidates, Kerastem™ and Prokinase™.
- Expanding its product pipeline through internal development and strategic acquisitions.
- Entering into partnerships with other companies to accelerate its growth.
Recent Acquisitions
ProPhase Labs has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating
Rating
Based on an AI-based assessment of its fundamentals, ProPhase Labs receives a rating of 7 out of 10.
Justification
The rating is based on the company's promising product candidates, strong intellectual property portfolio, and experienced leadership team. However, the company faces challenges related to its early stage of development and limited financial resources.
Sources & Disclaimers
- ProPhase Labs Inc. website: www.prophaselabs.com
- SEC filings: www.sec.gov
- Market research reports: www.statista.com
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
| Exchange | NASDAQ | Headquaters | Garden City, NY, United States |
| IPO Launch date | 1997-01-16 | Chairman & CEO | Mr. Ted William Karkus |
| Sector | Healthcare | Website | https://www.prophaselabs.com |
| Industry | Diagnostics & Research | Full time employees | 113 |
| Headquaters | Garden City, NY, United States | ||
| Chairman & CEO | Mr. Ted William Karkus | ||
| Website | https://www.prophaselabs.com | ||
| Website | https://www.prophaselabs.com | ||
| Full time employees | 113 |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.